Technology | May 05, 2015

Biotronik Brings Closed Loop Simulation Sensor to Cardiac Resynchronization Defibrillators

Technology better mimics human nervous system to adjust heart whether user is stationary or in motion

Biotronik, CLS, Itrevia, CRT-D, heart failure

May 5, 2015 — Biotronik announced that a unique physiologic sensor is now available in the latest family of cardiac resynchronization therapy defibrillator (CRT-D) devices. Closed Loop Stimulation (CLS) is the only cardiac sensor capable of appropriately adapting heart rate in response to physiologic demands independent of body movements or respiratory rate.

Chronotropic incompetence – the inability of the heart to increase its rate to keep up with increased activity or demand — is common in many heart failure patients. When programmed in a Biotronik device, CLS provides appropriate rate response, similar to patients with healthy sinus nodes.

Most other CRT-D devices use accelerometers, which are mechanisms that sense physical activity and require patients to be in motion before increasing their heart rate. Yet, patients need appropriate rate response regardless of whether they are actively moving or completely stationary. CLS more closely mimics the human nervous system, responding to patients’ metabolic changes. It can sense and respond to acute mental stress, adjusting the heart rate without relying on motion. CLS, available in Biotronik pacemakers since 2003, has been proven to be more responsive in activities of daily living than accelerometers.

“I've treated many patients with Biotronik’s pacemakers equipped with CLS and have had excellent results,” said Chad E. Bonhomme, M.D., cardiac electrophysiologist with Community Health Network in Indianapolis, Indiana. “CLS in ICDs offers a new and exciting option to more closely mimic normal physiology.

"In addition to rate adaptation, I look forward to seeing the potential benefits of increased exercise tolerance, improved heart variability and diminished orthostatic symptoms," continued Bonhomme.

The latest Biotronik Itrevia ICD and CRT-D series includes other advanced atrial therapies: morphology discrimination, Vp suppression, atrial capture control, improved ATP optimization and left ventricle (LV) pacing vectors. Combined, they create more therapeutic options to deliver effective therapy while reducing painful shocks. All devices include Biotronik Home Monitoring, a remote monitoring system with automatic daily transmission, which has been shown to reduce all-cause mortality by over 50 percent.

For more information: www.biotronik.com

Related Content

His Corrective Pacing Effective as an Initial Strategy for Heart Failure Cardiac Resynchronization CRT therapy vs. biventricular pacing (BiV) as a first-line strategy. #HRS #HRS19 #HRS2019
News | Cardiac Resynchronization Therapy Devices (CRT) | May 15, 2019 | Dave Fornell, Editor
May 15, 2019 — A pilot trial has shown His pacing in...
Biotronik Launches Acticor DX and CRT-DX Devices in U.S.
News | Cardiac Resynchronization Therapy Devices (CRT) | April 29, 2019
Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and CRT-DX devices....
Biotronik Launches Acticor and Rivacor ICD and CRT-D Devices in Europe
News | Cardiac Resynchronization Therapy Devices (CRT) | April 18, 2019
Biotronik announced the European market release of what it calls the world’s smallest implantable cardioverter...
Medtronic AdaptivCRT Feature Associated with Improved Heart Failure Patient Survival
News | Cardiac Resynchronization Therapy Devices (CRT) | May 22, 2018
Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved patient survival....
Medtronic Recalls CRT-Ds and ICDs Due to Manufacturing Error Preventing Electrical Shock Delivery
News | Cardiac Resynchronization Therapy Devices (CRT) | February 26, 2018
The U.S. Food and Drug Administration (FDA) announced that Medtronic is recalling certain implantable cardioverter...
Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD
Technology | Cardiac Resynchronization Therapy Devices (CRT) | January 03, 2018
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT) | August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT) | July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Overlay Init